Literature DB >> 10330036

Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors.

S Li1, S P Wu, M Whitmore, E J Loeffert, L Wang, S C Watkins, B R Pitt, L Huang.   

Abstract

Cationic lipid-mediated intravenous gene delivery shows promise in treating pulmonary diseases including lung tumor metastases, pulmonary hypertension, and acute respiratory distress syndrome. Nevertheless, clinical applications of cationic lipidic vectors via intravenous administration are limited by their transient gene expression. In addition, repeated dosing is not effective at frequent intervals. In an effort to elucidate the mechanism of gene inactivation, we report in this study that cationic lipid-protamine-DNA (LPD) complexes, but not each component alone, can induce a high level of cytokine production, including interferon-gamma and tumor necrosis factor-alpha. Furthermore, we demonstrate that LPD administration triggers apoptosis in the lung, a phenomenon that may be mediated in part by the two cytokines. Treatment of mice with antibodies against the two cytokines prolongs the duration of gene expression and also improves lung transfection on a second administration of LPD. Although the mechanism underlying LPD-induced cytokine production is unclear, methylation of the DNA significantly decreased the level of both interferon-gamma and tumor necrosis factor-alpha, suggesting that unmethylated CpG sequences in plasmid DNA play an important role. These data suggest that decreasing the CpG-mediated immune response while not affecting gene expression may be a useful therapeutic strategy to improve cationic lipid-mediated intravenous gene delivery to the lung.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10330036     DOI: 10.1152/ajplung.1999.276.5.L796

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  35 in total

Review 1.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 2.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

Review 3.  Design of modular non-viral gene therapy vectors.

Authors:  Laura De Laporte; Jennifer Cruz Rea; Lonnie D Shea
Journal:  Biomaterials       Date:  2005-10-21       Impact factor: 12.479

4.  Plasmid delivery in vivo from porous tissue-engineering scaffolds: transgene expression and cellular transfection.

Authors:  Jae-Hyung Jang; Christopher B Rives; Lonnie D Shea
Journal:  Mol Ther       Date:  2005-09       Impact factor: 11.454

Review 5.  Matrices and scaffolds for DNA delivery in tissue engineering.

Authors:  Laura De Laporte; Lonnie D Shea
Journal:  Adv Drug Deliv Rev       Date:  2007-04-14       Impact factor: 15.470

Review 6.  Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation.

Authors:  Ramalinga Kuruba; Annette Wilson; Xiang Gao; Song Li
Journal:  AAPS J       Date:  2009-01-09       Impact factor: 4.009

7.  Shear stress increases cytotoxicity and reduces transfection efficiency of liposomal gene delivery to CHO-S cells.

Authors:  Jyoti Rawat; Mugdha Gadgil
Journal:  Cytotechnology       Date:  2016-04-29       Impact factor: 2.058

8.  The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome.

Authors:  Weili Yan; Leaf Huang
Journal:  Int J Pharm       Date:  2008-10-15       Impact factor: 5.875

9.  The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.

Authors:  Jan L Bjersing; Kristina Eriksson; Andrej Tarkowski; L Vincent Collins
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

10.  Polyethylenimine-mediated gene delivery to the lung and therapeutic applications.

Authors:  Sante Di Gioia; Massimo Conese
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.